The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia.
A possible mechanism underlying the modulatory role of dopamine, adenosine and acetylcholine in the modification of corticostriatal synapses, subsequent changes in signal transduction through the "direct" and "indirect" pathways in the basal ganglia and variations in thalamic and neocortical cell activity is proposed. According to this mechanism, simultaneous activation of dopamine D1/D2 receptors as well as inactivation of adenosine A1/A(2A) receptors or muscarinic M4/M1 receptors on striatonigral/striatopallidal inhibitory cells can promote the induction of long-term potentiation/depression in the efficacy of excitatory cortical inputs to these cells. Subsequently augmented inhibition of the activity of inhibitory neurons of the output nuclei of the basal ganglia through the "direct" pathway together with reduced disinhibition of these nuclei through the "indirect" pathway synergistically increase thalamic and neocortical cell firing. The proposed mechanism can underlie such well known effects as "excitatory" and "inhibitory" influence of dopamine on striatonigral and striatopallidal cells, respectively; the opposite action of dopamine and adenosine on these cells; antiparkinsonic effects of dopamine receptor agonists and adenosine or acetylcholine muscarinic receptor antagonists.
Neurophysiology of Learning Laboratory, Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, 117865, Butlerova 5a str., Moscow, Russia. isabella.silkis@mtu-net.ru
I
I
Silkis
D000241:Adenosine / Q000494:pharmacology; D001479:Basal Ganglia / Q000187:drug effects / Q000502:physiology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000494:pharmacology; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000503:physiopathology; D017774:Long-Term Potentiation; D008959:Models, Neurological; D009069:Movement Disorders / Q000503:physiopathology; D009434:Neural Pathways / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D015398:Signal Transduction; D013569:Synapses / Q000502:physiology; D013788:Thalamus / Q000187:drug effects / Q000502:physiology*
D000241:Adenosine; D004298:Dopamine